LUMICKS creates technologies for dynamic single-molecule and cell avidity analysis. Our latest instrument, the z-Movi® Cell Avidity Analyzer, enables the measurement and selection of immune cells based on their interactions with cancer cells, providing a new parameter for experimentally evaluating immune cell functionality and activation. With this technology, scientists can measure cell avidity and obtain predictive, reproducible, and high-throughput results to compare several types of immunotherapeutic strategies, including CAR T cells, TCR T cells, bispecific antibodies, and NK cells.